Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark ... The Senza HFX ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

A $2.5 million federal grant will fund a four-year study led by Kessler Foundation scientist Karen J. Nolan, PhD, to explore ...

using spinal cord transcutaneous stimulation (scTS). This promising approach to enhance cardiovascular regulation addresses the challenges of unstable blood pressure and the accompanying ...